GLSI - Greenwich LifeSciences, Inc. News

Sectors

GLSI

Greenwich LifeSciences, Inc.

14.71

1 x 14.51

1 x 14.81

bid

ask

0.06

0.41%

10:03 AM

timesize

Ytd	-29.99%
1y	32.05%

14.38

day range

14.81

7.78

52 week range

34.10

Open	14.38	Prev Close	14.65	Low	14.38	High	14.81	Mkt Cap	215.04M
Vol	22.92K	Avg Vol	154.33K	EPS	-1.31	P/E	-11.18	Forward P/E	-14.83
Beta	1.40	Short Ratio	21.41	Inst. Own	8.70%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	22.91	200-d Avg	20.14	1yr Est	38.00

GLSI News

globenewswire.com

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

benzinga.com

Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of

FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended

globenewswire.com

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

benzinga.com

Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic

globenewswire.com

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

seekingalpha.com

Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-posi

benzinga.com

Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01

All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously

globenewswire.com

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMI

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meetin

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Gree

globenewswire.com

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

benzinga.com

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial

globenewswire.com

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meetin

STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

globenewswire.com

Greenwich LifeSciences Provides Update on Financing Strategy

STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the

seekingalpha.com

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences (GLSI) remains a "Buy" as phase 3 FLAMINGO-01 advances in HER2-positive breas

benzinga.com

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Mo

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com

Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tues

benzinga.com

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving I

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Frid

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Stocks That Hit 52-Week Lows On Monday

On Monday, 369 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Monday

During Monday's trading, 1214 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 807 companies reached new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 211 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Thursday

During Thursday, 849 stocks hit new 52-week lows.